

## FINANCIAL TEAR SHEET

### Corporate Profile

Adaptimmune is a leader in the TCR T-cell therapy space focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets - whether intracellular or surface expressed - for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides in order to target and potentially destroy cancer cells in patients.

Our wholly-owned pipeline of SPEAR T-cell therapies and targets continues to evolve; SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we continue to build a pipeline of proprietary TCR therapeutic candidates: We have identified over 25 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs. We believe these research programs are relevant to a wide range of cancer indications.

We believe our approach will lead to SPEAR therapeutic candidates that have the potential to significantly impact cancer treatment and the clinical outcomes of patients with cancer.

### Primary IR Contact

Investor Contact

**Email:**

[IR@adaptimmune.com](mailto:IR@adaptimmune.com)

# Stock Performance

## ADAP (AMERICAN DEPOSITARY SHARES)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$10.44</b>
Change (%)	▼ 0.54 (4.92%)
Volume	535,152
52 Week Low	\$4.82
Market Cap	\$5,897,137,982
Rolling EPS	-0.74
PE Ratio	0
Shares Outstanding	564,859,960

Data as of 07/20/18 4:00 p.m. ET



## Recent Headlines & Events

07/18/18

[Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts](#)

06/11/18

[Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self-renewing, and Capable of Persistent Anti-Tumor Effects](#)

06/04/18

[Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO](#)

There are currently no events scheduled.

## SEC Filings

**FILING DATE**

**FORM**

## Corporate Governance

[James Noble](#)

Chief Executive Officer

07/18/18	<u>8-K</u>	<u>Bent Jakobsen, PhD</u>	Scientific Founder
07/12/18	<u>S-3ASR</u>	<u>Helen Tayton-Martin, PhD, MBA</u>	Chief Business Officer
07/06/18	<u>3</u>	<u>Rafael Amado, MD</u>	Chief Medical Officer
07/06/18	<u>8-K</u>	<u>Adrian Rawcliffe</u>	Chief Financial Officer
		<u>Gwendolyn Binder, PhD</u>	Chief Technology Officer
		<u>William (Bill) Bertrand</u>	Chief Operating Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.